Skip to content
10-K/A

Annual Report

AVAI BIO, INC. AVAI

0001740797-25-000017

← back to feed
Filed
Feb 19, 2025 12:00 AM ET
Period of report
Amendment. Amends a previously filed report.
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Jul 3, 2024 117.02M sh
Operating Cash Flow FY 2024 · Mar 31, 2024 −$1.32M
Operating Cash Flow restated FY 2024 · Mar 31, 2023 −$54.46K
Cash And Equivalents FY 2024 · Mar 31, 2024 $281
Cash And Equivalents FY 2024 · Mar 31, 2023 $107.47K
Stockholders Equity FY 2024 · Mar 31, 2024 −$1.47M
Stockholders Equity FY 2024 · Mar 31, 2023 −$633.26K
Stockholders Equity FY 2024 · Mar 31, 2022 −$405.56K
Current Liabilities FY 2024 · Mar 31, 2024 $1.79M
Current Liabilities FY 2024 · Mar 31, 2023 $874.72K
Total Liabilities FY 2024 · Mar 31, 2024 $1.79M
Total Liabilities FY 2024 · Mar 31, 2023 $874.72K
Current Assets FY 2024 · Mar 31, 2024 $116.08K
Current Assets FY 2024 · Mar 31, 2023 $107.58K
Total Assets FY 2024 · Mar 31, 2024 $322.01K
Total Assets FY 2024 · Mar 31, 2023 $241.46K
Eps Basic FY 2024 · Mar 31, 2024 −$0.02
Eps Basic FY 2024 · Mar 31, 2023 $0.00
Sga Expense FY 2024 · Mar 31, 2024 $1.42M
Sga Expense restated FY 2024 · Mar 31, 2023 $234.91K
Net Income FY 2024 · Mar 31, 2024 −$2.13M
Net Income FY 2024 · Mar 31, 2023 −$348.93K
Operating Income FY 2024 · Mar 31, 2024 −$2.13M
Operating Income restated FY 2024 · Mar 31, 2023 −$348.93K
Gross Profit restated FY 2024 · Mar 31, 2023 −$40.45K
Cost Of Revenue FY 2024 · Mar 31, 2023 $276.32K
Revenue FY 2024 · Mar 31, 2023 $276.32K